Indeed, after careful examination, a WHO expert panel concluded that the drug “has no significant impact on mortality, nor are there any other significant beneficial effects for patients with regard to the need for artificial respiration or the time required. to recover”. Moreover, it is still possible that the drug could be harmful to patients. And then there is the high cost price, it says in the article.
Remdesivir was originally developed by the American pharmaceutical company Gilead to fight the Ebola virus. After the global corona pandemic broke out, the virus inhibitor was for a time seen as a beacon of hope in the fight against COVID-19. In July, Remdesivir became the first drug in Europe to be conditionally approved for the specific treatment of certain COVID patients.
Recently, however, tests suggested that the drug’s beneficial impact is minimal at best. The findings stem from a study coordinated by the WHO, which examined thousands of patients in nearly 500 clinics in more than 30 countries.
–
